Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib
Danian Nie, Kezhi Huang, Songmei Yin, et al.
Cell Death Discovery (2018) Vol. 4, Iss. 1
Open Access | Times Cited: 21

Showing 21 citing articles:

The nuclear export protein XPO1 — from biology to targeted therapy
Asfar S. Azmi, Md. Hafiz Uddin, Ramzi M. Mohammad
Nature Reviews Clinical Oncology (2020) Vol. 18, Iss. 3, pp. 152-169
Closed Access | Times Cited: 197
Exercise-Induced Reduction of IGF1R Sumoylation Attenuates Neuroinflammation in APP/PS1 Transgenic Mice
Yisheng Chen, Xiaofeng Chen, Zhiwen Luo, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 19
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
Lingyue Gao, Zhuo‐Xun Wu, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2021) Vol. 57, pp. 100770-100770
Closed Access | Times Cited: 96
Selinexor for the treatment of multiple myeloma
Klaus Podar, Jatin J. Shah, Ajai Chari, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 4, pp. 399-408
Closed Access | Times Cited: 57
Positive Feedback Regulation between KLF5 and XPO1 Promotes Cell Cycle Progression of Basal like Breast Cancer
Yu Tang, Rui Liu, Jing Zhu, et al.
Advanced Science (2025)
Open Access
Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy
Stella Newell, Pauline J. van der Watt, Virna D. Leaner
IUBMB Life (2023) Vol. 76, Iss. 1, pp. 4-25
Open Access | Times Cited: 12
KPT-330, A New Candidate Drug for Targeting NOTCH1 Overexpression in T-cell Acute Lymphoblastic Leukemia, An In Vitro and Silico Study
Farah Naz, Saima Ejaz, Tajuddeen Adam Wali, et al.
Cell Biochemistry and Biophysics (2025)
Closed Access
Cisplatin Dependent Secretion of Immunomodulatory High Mobility Group Box 1 (HMGB1) Protein from Lung Cancer Cells
Kevin P. Gillespie, Ross Pirnie, Clementina Mesaros, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1335-1335
Open Access | Times Cited: 9
Pharmacoepigenetic Processors: Epigenetic Drugs, Drug Resistance, Toxicoepigenetics, and Nutriepigenetics
Ramón Cacabelos, Juan C. Carril, Ana Sanmartín, et al.
Elsevier eBooks (2019), pp. 191-424
Closed Access | Times Cited: 28
Dynamic Single-Cell RNA-Seq reveals mechanism of Selinexor-Resistance in Chronic myeloid leukemia
Yunqi Cui, Yating Li, Jiamei Ji, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112212-112212
Open Access | Times Cited: 2
Hitting a moving target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic approach in cancer
Maria Sendino, Miren Josu Omaetxebarria Ibarra, José A. Rodríguez
Cancer Drug Resistance (2018)
Open Access | Times Cited: 23
MiR‐483‐3p improves learning and memory abilities via XPO1 in Alzheimer's disease
Gang Luo, Xiaoyan Wang, Changya Liu
Brain and Behavior (2022) Vol. 12, Iss. 8
Open Access | Times Cited: 12
Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies
Alessandro Allegra, Vanessa Innao, Andrea Gaetano Allegra, et al.
Clinical Lymphoma Myeloma & Leukemia (2019) Vol. 19, Iss. 11, pp. 689-698
Closed Access | Times Cited: 17
The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression
Manman Deng, Jinshui Tan, Ziying Fan, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity
Moritz von Fallois, Friederike Katharina Kosyna, Markus Mandl, et al.
Journal of Cancer Research and Clinical Oncology (2021) Vol. 147, Iss. 7, pp. 2025-2033
Open Access | Times Cited: 11
AMP‐activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR‐ABL protein in CML cells
Daisuke Koyama, Jiro Kikuchi, Yoshiaki Kuroda, et al.
Cancer Science (2020) Vol. 112, Iss. 1, pp. 194-204
Open Access | Times Cited: 11
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair
Jithma P. Abeykoon, Xiaosheng Wu, Kevin E. Nowakowski, et al.
Blood (2020) Vol. 137, Iss. 4, pp. 513-523
Open Access | Times Cited: 11
Prognostic and therapeutic significance of XPO1 in T-cell lymphoma
Danian Nie, Xiaohui Xiao, Jiaoting Chen, et al.
Experimental Cell Research (2022) Vol. 416, Iss. 2, pp. 113180-113180
Closed Access | Times Cited: 7
Cisplatin Dependent Secretion of Immunomodulatory High Mobility Group Box 1 (HMGB1) Protein from Lung Cancer Cells
Kevin P. Gillespie, Ross Pirnie, Clementina Mesaros, et al.
(2023)
Open Access | Times Cited: 3
RanBP3 Regulates Proliferation, Apoptosis and Chemosensitivity of Chronic Myeloid Leukemia Cells via Mediating SMAD2/3 and ERK1/2 Nuclear Transport
Qian Li, Zhenglan Huang, Yuhang Peng, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 5
HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs
Mailee Huynh, Hae Yeun Chang, Dominique N. Lisiero, et al.
PLoS ONE (2022) Vol. 17, Iss. 12, pp. e0274704-e0274704
Open Access | Times Cited: 3
Advances in Drug Therapy for Gastrointestinal Stromal Tumour
Ju Liu, Jiawei Li, Yan Zhu, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 21, pp. 3057-3073
Closed Access
Page 1

Scroll to top